Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03959800 · ClinicalTrials.gov registry record
Molecular Basis of Pediatric Liver Cancer
A clinical trial of Hepatocellular Carcinoma and Hepatoblastoma, sponsored by University of Pittsburgh.
- Recruiting
- Registry status
- 1,600
- Enrollment target
- 1
- Study location
NCT03959800 is a study of Hepatocellular Carcinoma and Hepatoblastoma that is actively recruiting participants, run by University of Pittsburgh. The registered enrollment target is 1,600 participants, above the 246-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (550% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03959800, a study of Hepatocellular Carcinoma and Hepatoblastoma, is actively recruiting participants, sponsored by University of Pittsburgh.
- RECRUITING
- Registry status
- 1,600 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this retrospective and prospective project is to understand the molecular and genetic basis of liver cancer of childhood. Understanding the molecular and genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.
Conditions Studied
Study Locations (1)
Pennsylvania
- UPMC Children's Hospital of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,600 participants |
| Start Date | 2015-06-22 |
| Est. Completion | 2029-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03959800
The ClinicalTrials.gov registry entry for NCT03959800 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 246-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (550% higher). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT03959800 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03959800 about?
NCT03959800 is a clinical study titled "Molecular Basis of Pediatric Liver Cancer". The purpose of this retrospective and prospective project is to understand the molecular and genetic basis of liver cancer of childhood. Understanding the molecular and genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.
What is the current status of trial NCT03959800?
This trial is currently recruiting. The enrollment target is 1,600 participants. The study started on 2015-06-22. Estimated completion is 2029-06-30.
What conditions does trial NCT03959800 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Hepatoblastoma, Childhood Liver Cancer, Liver Malignant Tumors, Embryonal Sarcoma of Liver (Disorder).
Who is sponsoring clinical trial NCT03959800?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03959800 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.